Menu

Sea Anemone Toxin Could Treat Autoimmunity

If successful, the treatments could alleviate patients’ pain by reducing inflammation.

Jan 1, 2018
Jef Akst

© ISTOCK.COM/DAMOCEANIn the early days of searching for interesting compounds in animal venoms, researchers regularly discovered molecules that blocked voltage-gated sodium channels. While these channels play critical roles in pain perception, the protein family that makes up the channels also mediates other physiological functions, so the challenge became to block channels only on cells involved in pain. “It’s all about selectivity,” says Christine Beeton, an immunologist at Baylor College of Medicine.

In the mid-1990s, researchers discovered an alternative—stichodactyla toxin (ShK) from a Caribbean sea anemone (Stichodactyla helianthus), one of the first peptide toxins identified that blocks a voltage-gated potassium channel. And not just any potassium channel; ShK targets KV1.3, which is upregulated on autoreactive T lymphocytes—cells that drive numerous autoimmune diseases, Beeton explains. “That makes this channel a very, very good target, because now you can target autoreactive T lymphocytes without targeting all the T lymphocytes in the body, so you’re not completely immunocompromising the patients.”

In 2001, Beeton started working on ShK as a postdoc at the University of California, Irvine. There she helped develop the analog ShK-186—so called because it was the 186th compound tested—which was highly selective for the KV1.3 channel and bound to it with a high affinity. Now known as dalazatide, the drug is being developed by Seattle-based Kineta for the treatment of multiple autoimmune disorders, including psoriasis (the only indication for which dalazatide has progressed to early-stage human trials), inclusion-body myositis, and lupus. While dalazatide is not an analgesic per se, “each time you have an inflammatory disease, if you manage to reduce this inflammation, as an effect you’re going to reduce pain also,” Beeton says.

Read about other animal groups researchers are exploring for pain-killing leads in the full feature story, “Animal Analgesics.”

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Getting More Consistent Results by Knowing the Quality of Your Protein
Getting More Consistent Results by Knowing the Quality of Your Protein
Download this guide from NanoTemper to learn how to identify and evaluate the quality of your protein samples!
Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing